Randomised controlled double-blind trial of DNA ME-TRAP/MVA ME-TRAP against malaria infection in Gambians aged 15 to 45

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN05221133

Enrollment

372

Registered

2004-10-05

Start date

2002-07-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasmodium falciparum malaria Infections and Infestations Malaria

Interventions

Intervention: Deoxyribonucleic Acid (DNA) Multiple Epitope (ME)-Thrombospondin Related Adhesion Protein (TRAP) malaria vaccination followed by Modified Vaccinia virus Ankara (MVA) ME-TRAP malaria vac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 372 Healthy Gambian men aged 15 to 45 2. Resident in villages in the North Bank Division

Exclusion criteria

Exclusion criteria: No exclusion criteria provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. Vaccine safety 2. Immunogenicity 3. Time to first P. falciparum infection	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Gambia, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026